Kymera Therapeutics, Inc. (KYMR) Balance Sheet

The balance sheet has expanded significantly, with total assets nearly doubling from $868.3M to $1.6B over the period, but this growth is primarily attributable to financing activities rather than operational profitability. Retained earnings have become increasingly negative, indicating that the company continues to consume capital at a rapid pace, with cumulative losses exceeding $1.2B as of 2026Q2. This suggests that while the company has successfully accessed capital markets, its underlying business model remains in a pre-revenue or early-revenue stage, and the trajectory of equity growth is not yet self-sustaining.

The company's leverage is minimal, with a D/E ratio of 0.05 and total debt of $82.2M, which is modest relative to its $1.5B equity base. However, this low leverage appears to be a choice rather than a necessity, as the company has funded its operations through equity raises, evidenced by the significant increase in equity from $711.2M to $1.5B. The absence of substantial debt reduces refinancing risk, but it also implies that the company is not using debt to extend its cash runway, which may indicate that management prefers to avoid fixed obligations given the uncertainty of future cash flows.

The asset base is dominated by cash and other current assets, with property, plant, and equipment (PPE) declining from $100.4M in 2024Q2 to $81.1M in 2026Q2, indicating a research-driven operation with limited capital intensity. The absence of goodwill suggests that the company has not engaged in significant acquisitions, which reduces the risk of impairment charges. However, the declining PPE may indicate that the company is not investing heavily in physical infrastructure, which is consistent with a biotech that outsources manufacturing and relies on partnerships for development.

The equity account has grown substantially, but this growth is almost entirely attributable to external financing, as evidenced by the deepening negative retained earnings balance. The company has not generated positive retained earnings in any quarter, and the cumulative deficit has grown from -$579.3M to -$1.2B over the period. This suggests that while the company has been successful in raising capital, it has not yet achieved the operational scale or profitability needed to sustain its balance sheet without continued external support. Investors should monitor the pace of capital raises relative to cash burn, as dilution may become a concern if the company cannot achieve profitability.

The company maintains a strong current ratio of 9.83, indicating ample short-term liquidity relative to current liabilities. However, cash and cash equivalents of $124.5M are relatively low compared to the company's quarterly operating burn, which has averaged over $80M in recent quarters. This suggests that the company may need to raise additional capital in the near term to fund its operations, unless it can secure significant partnership payments or reduce expenses. The high current ratio is somewhat misleading because it is driven by a large cash balance that is being consumed rapidly, and the company's ability to weather a prolonged downturn in funding availability is limited.